The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth
Open accessAbstract
BACKGROUND: Interleukin-8 (IL-8) is a proangiogenic cytokine that is overexpressed in many human cancers. We investigated the clinical and biologic significance of IL-8 in ovarian carcinoma using human samples and orthotopic mouse models. METHODS: Tumor expression of IL-8 was assessed by immunohistochemistry among ovarian cancer patients (n = 102) with available clinical and survival data. We examined the effect of IL-8 gene silencing with small interfering RNAs incorporated into neutral liposomes (siRNA-DOPCs), alone and in combination with docetaxel, on in vivo tumor growth, angiogenesis (microvessel density), and tumor cell proliferation in mice (n = 10 per treatment group) bearing orthotopic taxane-sensitive (HeyA8 and SKOV3ip1) and taxane-resistant (SKOV3ip2.TR) ovarian tumors. All statistical tests were two-sided. RESULTS: Of the 102 cancer specimens, 43 (42%) had high IL-8 expression and 59 (58%) had low or no IL-8 expression; high IL-8 expression was associated with advanced tumor stage (P = .019), high tumor grade (P = .031), and worse survival (median survival for patients with high vs low IL-8 expression: 1.62 vs 3.79 years; P < .001). Compared with empty liposomes, IL-8 siRNA-DOPC reduced the mean tumor weight by 32% (95% confidence interval [CI] = 14% to 50%; P = .03) and 52% (95% CI = 27% to 78%; P = .03) in the HeyA8 and SKOV3ip1 mouse models, respectively. In all three mouse models, treatment with IL-8 siRNA-DOPC plus the taxane docetaxel reduced tumor growth the most compared with empty liposomes (77% to 98% reduction in tumor growth; P < .01 for all). In the HeyA8 and SKOV3ip1 models, tumors from mice treated with IL-8 siRNA-DOPC alone had lower microvessel density than tumors from mice treated with empty liposomes (HeyA8: 34% lower, 95% CI = 32% to 36% lower [P = .002]; SKOV3ip1: 39% lower, 95% CI = 34% to 44% lower [P = .007]). Compared with empty liposomes, IL-8 siRNA-DOPC plus docetaxel reduced tumor cell proliferation by 35% (95% CI = 25% to 44%; P < .001) and 38% (95% CI = 28% to 48%; P < .001) in the HeyA8 and SKOV3ip1 models, respectively. CONCLUSIONS: Increased IL-8 expression is associated with poor clinical outcome in human ovarian carcinoma, and IL-8 gene silencing decreases tumor growth through antiangiogenic mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Interleukin-8 as a macrophage-derived mediator of angiogenesis
Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., & Strieter, R. M. (1992) · Science · doi:10.1126/science.1281554 · Cited by 2,135
Li, A., Dubey, S., Varney, M. L., Dave, B. J., & Singh, R. K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3369 · Cited by 1,332
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., Jennings, N. B., Armaiz-Pena, G., Bankson, J. A., Ravoori, M., et al. (2006) · Nature Medicine · doi:10.1038/nm1447 · Cited by 1,320
Self-citationLessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Principles and Practice of Gynecologic Oncology
Hoskins, W. J., Pérez, C. A., & Young, R. C. (1992) · Cited by 945
Principles and Practice of Gynecologic Oncology
Moore, W. (1997) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199707000-00022 · Cited by 838
Interleukin-8 and human cancer biology
Xie, K. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00016-8 · Cited by 689
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Self-citationInterleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF
Matsushima, K., & Oppenheim, J. J. (1989) · Cytokine · doi:10.1016/1043-4666(89)91043-0 · Cited by 607
Walz, A., Peveri, P., Aschauer, H., & Baggiolini, M. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90432-3 · Cited by 505
Stress hormone-mediated invasion of ovarian cancer cells
Sood, A. K., Bhatty, R., Kamat, A. A., Landen, C. N., Han, L., Thaker, P. H., Li, Y., Gershenson, D. M., Lutgendorf, S., & Cole, S. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1698 · Cited by 491
Self-citationRegulation of Interleukin-8 Gene Expression
Roebuck, K. A. (1999) · Journal of Interferon & Cytokine Research · doi:10.1089/107999099313866 · Cited by 415
Luca, M., Huang, S., Gershenwald, J. E., Singh, R. K., Reich, R., & Bar‐Eli, M. (1997) · Europe PMC (PubMed Central) · Cited by 414
Self-citationExpression of Angiogenesis-Related Genes and Progression of Human Ovarian Carcinomas in Nude Mice
Yoneda, J., Kuniyasu, H., Price, J. E., Bucana, C. D., Fidler, I. J., & Crispens, M. A. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.6.447 · Cited by 375
Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X.-D., Gudas, J. M., & Bar-Eli, M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64164-8 · Cited by 361
Self-citationChemokine binding and activities mediated by the mouse IL-8 receptor
Lee, J., Cacalano, G., Camerato, T., Toy, K., Moore, M. W., & Wood, W. I. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.4.2158 · Cited by 348
The role of VEGF in the regulation of physiological and pathological angiogenesis
Ferrara, N. (2005) · Mechanisms of Angiogenesis · doi:10.1007/3-7643-7311-3_15 · Cited by 312
siRNA therapeutics: big potential from small RNAs
Ryther, R. C. C., Flynt, A. S., Phillips, J. A., & Patton, J. G. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302356 · Cited by 301
Halder, J., Kamat, A. A., Landen, C. N., Han, L. Y., Lutgendorf, S. K., Lin, Y. G., Merritt, W. M., Jennings, N. B., Chavez-Reyes, A., Coleman, R. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0021 · Cited by 297
Self-citationLi, A., Varney, M. L., Valasek, J., Godfrey, M., Dave, B. J., & Singh, R. K. (2005) · Angiogenesis · doi:10.1007/s10456-005-5208-4 · Cited by 285
CXC CHEMOKINE RECEPTOR EXPRESSION ON HUMAN ENDOTHELIAL CELLS
Murdoch, C., Monk, P. N., & Finn, A. (1999) · Cytokine · doi:10.1006/cyto.1998.0465 · Cited by 271
Bozic, C. R., Gerard, N. P., von Uexkull-Guldenband, C., Kolakowski, L. F., Conklyn, M. J., Breslow, R., Showell, H. J., & Gerard, C. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43882-3 · Cited by 256
Role of Interleukin-8 in Tumor Growth and Metastasis of Human Melanoma
Bar-Eli, M. (1999) · Pathobiology · doi:10.1159/000028045 · Cited by 247
Self-citationHendrix, M. J. C., Seftor, E. A., Seftor, R. E. B., & Fidler, I. J. (1987) · Cancer Letters · doi:10.1016/0304-3835(87)90209-6 · Cited by 240
Identification of C5ades arg and an Anionic Neutrophil-Activating Peptide (ANAP) in Psoriatic Scales
Schröder, J.-M., & Christophers, E. (1986) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12523566 · Cited by 224
EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma
Thaker, P. H., Deavers, M., Celestino, J., Thornton, A., Fletcher, M. S., Landen, C. N., Kinch, M. S., Kiener, P. A., & Sood, A. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0589 · Cited by 211
Self-citationKim, S. J., Uehara, H., Karashima, T., Mccarty, M., Shih, N., & Fidler, I. J. (2001) · Neoplasia · doi:10.1038/sj.neo.7900124 · Cited by 206
Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.
Cooper, B. C., Ritchie, J. M., Broghammer, C. L. W., Coffin, J. E., Sorosky, J. I., Buller, R. E., Hendrix, M. J. C., & Sood, A. K. (2002) · PubMed · Cited by 169
Self-citationHirte, H. W., Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B. E., Tu, D., Sadura, A., Brundage, M., & Seymour, L. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.020 · Cited by 152
Mian, B. M., Dinney, C. P., Bermejo, C. E., Sweeney, P., Tellez, C. S., Yang, X., Gudas, J. M., McConkey, D. J., & Bar‐Eli, M. (2003) · PubMed · Cited by 148
Self-citationCirculating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer
Lokshin, A. E., Winans, M., Landsittel, D. P., Marrangoni, A., Velikokhatnaya, L., Modugno, F., Nolen, B. M., & Gorelik, E. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.011 · Cited by 144
Kassim, S. K., El-Salahy, E. M., Fayed, S. T., Helal, S. A., Helal, T., Azzam, E. E.-D., & Khalifa, A. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.01.014 · Cited by 144
Langley, R. R., Ramirez, K. M., Tsan, R. Z., Arsdall, M. R. V., Nilsson, M. B., & Fidler, I. J. (2003) · PubMed · Cited by 144
Self-citationKarashima, T., Sweeney, P., Kamat, A. M., Huang, S., Kim, S. J., Bar‐Eli, M., McConkey, D. J., & Dinney, C. P. (2003) · PubMed · Cited by 138
Self-citationEfficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer
Landen, C. N., Lu, C., Han, L. Y., Coffman, K. T., Bruckheimer, E., Halder, J., Mangala, L. S., Merritt, W. M., Lin, Y. G., Gao, C., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj414 · Cited by 136
Self-citationSmall molecule antagonists of proteins
Gadek, T. R., & Nicholas, J. B. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01479-x · Cited by 120
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer
Landen, C. N., Merritt, W. M., Mangala, L. S., Sanguino, A. M., Bucana, C. D., Lü, C., Lin, Y. G., Han, L. Y., Kamat, A. A., Schmandt, R. E., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.12.3468 · Cited by 119
Self-citationInterleukin 8: An Autocrine Growth Factor for Human Ovarian Cancer
Xu, L., & Fidler, I. J. (2001) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504001108747567 · Cited by 107
Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma
Han, L. Y., Landen, C. N., Trevino, J. G., Halder, J., Lin, Y. G., Kamat, A. A., Kim, T., Merritt, W. M., Coleman, R. L., Gershenson, D. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1410 · Cited by 94
Self-citationBioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL‐8
Melnikova, V. O., & Bar‐Eli, M. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00331.x · Cited by 87
Self-citationLamendola, D. E., Duan, Z., Yusuf, R. Z., & Seiden, M. V. (2003) · PubMed · Cited by 83
Cloning and characterization of mouse homolog of the CXC chemokine receptor CXCR1
Fu, W., Zhang, Y., Zhang, J., & Chen, W. (2005) · Cytokine · doi:10.1016/j.cyto.2005.02.005 · Cited by 81
Thaker, P. H., Yazıcı, S., Nilsson, M. B., Yokoi, K., Tsan, R. Z., He, J., Kim, S.-J., Fidler, I. J., & Sood, A. K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2060 · Cited by 80
Self-citationThe Chemotactic Cytokine Interleukin-8—A Cyst Fluid Marker for Malignant Epithelial Ovarian Cancer?
Ivarsson, K., Runesson, E., Sundfeldt, K., Haeger, M., Hedin, L., Janson, P. O., & Brännström, M. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5198 · Cited by 71
A homolog of the human chemokine receptor CXCR1 is expressed in the mouse
Moepps, B., Nuesseler, E., Braun, M., & Gierschik, P. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.06.043 · Cited by 70
Lara, P. N., Stadler, W. M., Longmate, J., Quinn, D. I., Wexler, J. A., Loan, M. V., Twardowski, P. W., Gumerlock, P. H., Vogelzang, N. J., Vokes, E. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2074 · Cited by 68
The prognostic variability of ovarian tumor grading by different pathologists
Baak, J. P. A., Langley, F. A., Talerman, A., & Delemarre, J. F. M. (1987) · Gynecologic Oncology · doi:10.1016/0090-8258(87)90289-7 · Cited by 59
Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology
Fasciani, A., D’Ambrogio, G., Bocci, G., Luisi, S. V., Artini, P. G., & Genazzani, A. R. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)01804-0 · Cited by 55
Trevino, J. G., Gray, M. J., Nawrocki, S. T., Summy, J. M., Lesslie, D. P., Evans, D. B., Sawyer, T. K., Shakespeare, W. C., Watowich, S. S., Chiao, P. J., et al. (2006) · Angiogenesis · doi:10.1007/s10456-006-9038-9 · Cited by 52
Expression of metastasis-related genes in human epithelial ovarian tumors
Herrera, C., Xu, L., Bucana, C. D., Silva, E., Hess, K. R., Gershenson, D. M., & Fidler, I. J. (2002) · International Journal of Oncology · doi:10.3892/ijo.20.1.5 · Cited by 38
Cloning of a cDNA encoding a mouse homolog of the interleukin-8 receptor
Harada, A., Kuno, K., Nomura, H., Mukaida, N., Murakami, S., & Matsushima, K. (1994) · Gene · doi:10.1016/0378-1119(94)90278-x · Cited by 37
藤野, 晴., Kondo, K., Ishikura, H., Maki, H., Kinoshita, H., Miyoshi, T., Takahashi, Y., Sawada, N., Takizawa, H., Nagao, T., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0031 · Cited by 21
Overcoming obstacles to monoclonal antibody product development and approval
Stein, K. E. (1997) · Trends in biotechnology · doi:10.1016/s0167-7799(96)10075-5 · Cited by 19
Cited by
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2492 · Cited by 2,279
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer
Merritt, W. M., Lin, Y. G., Han, L. Y., Kamat, A. A., Spannuth, W. A., Schmandt, R., Urbauer, D., Pennacchio, L. A., Cheng, J.-F., Nick, A. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803785 · Cited by 712
Self-citationsiRNA delivery systems for cancer treatment
Oh, Y.-K., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 645
Hennessy, B. T., Coleman, R. L., & Markman, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61338-6 · Cited by 640
Metadata
- Authors
- Merritt, W. M., Lin, Y. G., Spannuth, W. A., Fletcher, M. S., Kamat, A. A., Han, L. Y., Landen, C. N., Jennings, N., De Geest, K., Langley, R. R., Villares, G., Sanguino, A., Lutgendorf, S. K., Lopez-Berestein, G., Bar-Eli, M. M., & Sood, A. K.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-05
- Volume
- 100
- Issue
- 5
- Pages
- 359-372
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2106601257
- Cited by
- 257
- References
- 54
- FWCI
- 26.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.